OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programmeECCO '18 Vienna
2018
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populationsECCO '18 Vienna
2018
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort studyECCO '18 Vienna
2018
OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammationECCO '18 Vienna
2018
P001: Establishment of in vitro human model for ulcerative colitis by using human colon organoid cultureECCO '18 Vienna
2018
P002: Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 familyECCO '18 Vienna
2018
P003: Identification of a novel therapeutic agent for treating Crohn’s disease guided by systems medicineECCO '18 Vienna
2018
P004: Altered colonic mucosal oxylipins and endocannabinoids levels in treatment-naive and deep remission ulcerative colitis patientsECCO '18 Vienna
2018
P005: A multi-marker serum test to assess the presence of ulcerations in infliximab treated patients with Crohn’s diseaseECCO '18 Vienna
2018
P007: Activation of pH-sensing receptor OGR1 (GPR68) induces ER stress and autophagy in an intestinal epithelial cell modelECCO '18 Vienna
2018
P008: Differences in macrophage infiltration and Wnt ligands expression between stricturing and penetrating behaviour in Crohn’s diseaseECCO '18 Vienna
2018
P009: Autophagy-related host factors are implicated in the incapability of macrophages from Crohn’s disease patients to mediate adherent-invasive E. coli clearanceECCO '18 Vienna
2018
P010: Serum proteomic profiling in Crohn’s disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrenceECCO '18 Vienna
2018